The Motley Fool

Is Paradigm Biopharmaceuticals the share market’s next huge winner?

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has rocketed over 2019 as excitement mounts over the biotech researcher’s potential to commercialise drugs designed to treat inflammatory conditions such as osteoarthritis.

On September 10 2019 it told investors that its ‘investigational new drug’ (IND) application has been cleared by the US healthcare regulator the FDA.

In effect it now has the green light to proceed with Phase III trials that could provide the clinical evidence needed to commercialise its pentosan polysulfate sodium-based drug to treat osteoarthritis.

According to Paradigm bulls or evangelists its pentosan polysulfate sodium-based drug has more than 1,000 possible indications in treating common human medical conditions. So in theory the company has some eye-watering potential.

As at 30 June 2019 it had $73.2 million cash on hand to show it’s a credible operator that the market has now bid up to a value around $491 million based on a $2.55 share price and around 192.5 million shares issue.

It also has the option to partner with big pharma to shoulder some of the high costs of Phase III and other clinical trials. Any partnership would be in return for some sort of financial or equity-related interest. 

The company has no sales as yet and remains a speculative bet only suitable for experienced investors confident in their research.

As a final disclaimer it’s also worth remembering these kind of stocks can often rise on excitement before crashing on reality, as such they can fall into the ‘buy the rumour, sell the news’ category. 

Other speccy biotechs for the punters include Mesoblast Limited (ASX: MSB) and Next Science Ltd (ASX: NXS).

NEW! Top 3 Dividend Bets for 2019

With interest rates likely to stay at rock bottom for months (or YEARS) to come, income-minded investors have nowhere to turn... except dividend shares. That’s why The Motley Fool’s top analysts have just prepared a brand-new report, laying out their top 3 dividend bets for 2019.

Hint: These are 3 shares you’ve probably never come across before.

They’re not the banks. Not Woolies or Wesfarmers or any of the “usual suspects.”

We think these 3 shares offer solid growth prospects over the next 12 months. Each of these three companies boasts fully franked yields and could be a great fit for your diversified portfolio. You’ll discover all three names and codes in "The Motley Fool’s Top 3 Dividend Shares for 2019."

Even better, your copy is free when you click the link below. Fair warning: This report is brand new and may not be available forever. Click the link below to be among the first investors to get access to this timely, important new research!

The names of these top 3 dividend bets are all included. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies move – we may be forced to remove this report.

Click here to claim your free copy right now!

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

FREE REPORT: Five Cheap and Good Stocks to Buy now…

Our Motley Fool experts have FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.